Goldman Sachs Maintains Neutral on Nautilus Biotechnology, Lowers Price Target to $2
Goldman Sachs analyst Matthew Sykes maintains Nautilus Biotechnology (NASDAQ:NAUT) with a Neutral and lowers the price target from $4 to $2.
Earnings Scheduled For August 2, 2022
Companies Reporting Before The Bell
• Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.
A Preview Of Nautilus Biotechnology’s Earnings
Nautilus Biotechnology (NASDAQ:NAUT) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement.
Analysts estimate that Nautilus Biotechnology will report an earnings per share (EPS) of $-0.17.
Earnings Scheduled For May 3, 2022
Companies Reporting Before The Bell
• Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.
Nautilus Biotechnology Q4 EPS $(0.13), Inline
Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.13) per share which met the analyst consensus estimate.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
Morgan Stanley Initiates Coverage On Nautilus Biotechnology with Equal-Weight Rating, Announces Price Target of $8
Morgan Stanley analyst Tejas Savant initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Equal-Weight rating and announces Price Target of $8.
50 Biggest Movers From Yesterday
Gainers
Society Pass Incorporated (NASDAQ: SOPA) shares surged 53.4% to settle at $16.31 on Wednesday.